 The M3 subtype of AML , also known as acute promyelocytic leukemia ( APL ) , is almost universally treated with the drug all @-@ trans @-@ retinoic acid ( ATRA ) in addition to induction chemotherapy , usually an anthracycline . Care must be taken to prevent disseminated intravascular coagulation ( DIC ) , complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation . APL is eminently curable , with well @-@ documented treatment protocols . 
 The M3 subtype of AML , also known as acute promyelocytic leukemia ( APL ) , is almost universally treated with the drug all @-@ trans @-@ retinoic acid ( ATRA ) in addition to induction chemotherapy , usually an anthracycline . Care must be taken to prevent disseminated intravascular coagulation ( DIC ) , complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation . APL <a href='drop_aux' title='1'><mark>is</mark></a>eminently curable , with well @-@ documented treatment protocols . 
Da M3 subtype of AML , also known as acute promyelocytic leukemia ( APL ) , is almost universally treated with tdadrug alll @-@ trans @-@ retinoic acid ( ATRA ) in addition to induction chemotherapy , usually an anthracycline . Care must b taken to prevent disseminated intravascular coagulation ( DIC ) , complicating thdareatment of APL when the promyelocytes release thedantents of their granules into the peripheral circulation . APL eminently curable , witt well @-@ documented treatment protocols .